Mouse L cell lines constitutively expressing glycoproteins B or D of herpes simplex virus type 1 (LTKgB and LTKgD respectively) were used to study the longevity of the immune response to these viral glycoproteins in mice. Two immunizations with the cell lines were necessary to induce a persisting antibody response (present for over 200 days). Only LTKgD induced a neutralizing antibody response in mice and this also remained at high titres over 200 days after two inoculations. The presence in mice of precursor cytotoxic T lymphocytes specific for gB expressed in the L cells was also shown up to 270 days after immunization. Mice immunized with the cell lines showed an increased rate of virus clearance from the ear pinna, inoculation with LTKgD resulting in more clearance than LTKgB at 7 days post-immunization, This type of protection was reduced with time after inoculation, until by day 161 there was no significant difference in virus titres between immunized and control groups. However, LTKgD immunization protected against the establishment of latent infections in the ganglia of mice even up to 186 days postinoculation.
Introduction
The use of the mouse model to study herpes simplex virus (HSV) infections has clarified many aspects of the immune response during the disease. It has shown that T cells are central to recovery from primary HSV infections (reviewed by Nash et al., 1985) . In particular, the independent in vivo depletion of either CD4 ÷ (L3T4 ÷) or CD8 ÷ (Lyt2 ÷) T cell subsets with monoclonal antibodies (MAbs) to these markers has shown the importance of CD4 ÷ T cells (MHC class II-restricted, T helper lymphocytes) in clearing HSV-1 from the periphery, although CD8 ÷ T cells (MHC class I-restricted, usually cytotoxic T lymphocytes) have a possible role in control of nervous system infections . Antibody does not appear to be as important as T cells during primary infections (Kapoor et al., 1982) and indeed, high antibody titres are not induced until after virus has been cleared from the site of a primary infection, but obviously it will be important in a secondary infection when pre-existing antibody may affect the course of the infection (Simmons & Nash, 1985) .
As HSV-1 is a very complex virus with at least 60 open reading frames (ORFs) for proteins (McGeoch et al., 1985 (McGeoch et al., , 1988 , there are many candidate virus antigens which could induce the above immune responses. Initial research showed that the surface glycoproteins of the virus induced good antibody responses (reviewed by Norrild, 1985) . The glycoproteins have also been implicated in class I-and class II-restricted T cell responses in both mice (Blacklaws et al., 1987; Carter et al., 1981; Chan et al., 1985; Jennings et al., 1984; Lawman et al., 1980; McLaughlinTaylor et al., 1988; Rosenthal et al., 1987; Schrier et al., 1983) and humans (Zarling et al., 1986) , although most work has been carried out with glycoproteins B and D of HSV-1. However, the immediate early proteins of HSV-1 have also been implicated in T cell responses (Martin et al., 1988) .
With interest in developing a subunit vaccine against HSV, information on the specific immune responses must also be combined with the ability of proteins to induce protective responses before candidates for inclusion in a vaccine may be determined. Protective responses induced by glycoproteins (including gB, gC and gD) have been reported in mice and guinea-pigs (Berman et al., 1985; Blacklaws et al., 1987; Cantin et al., 1987; Cremer et al., 1985; Long et al., 1984; Paoletti et al., 1984; Roberts et al., 1985; Sanchez-Pescador et al., 1988; Stanberry et al., 1987) . However, most of these studies have concerned protection shortly after immunization (i.e. within 30 days). As a vaccine should be protective for long periods of time, we have investigated the memory immune response of mice to mouse L cell lines constitutively expressing HSV-1 gB and gD many months after immunization. These include the antibody, cytotoxic T lymphocyte and protective responses of mice to gB and gD up to 200 days after immunization.
Methods
Mice. Female CBA mice, 8 to 12 weeks of age, were obtained from the Department of Pathology Animal House, University of Cambridge, U.K.
Viruses. HSV-1 strains SC16 and CI(101)TK-were all passaged at a low m.o.i, in BHK-21 cells and stocks of virus were stored at -70 °C. All viruses were titrated on BHK-21 cells.
Cells. LTKgB and LTKgD cells contain the HSV-1 strain KOS gB gene and strain Patton gD gene respectively, both expressed from the simian virus 40 early promoter and linked to HSV-1 thymidine kinase. The cell lines were established by transfection of LMTK-cells as detailed by Blacklaws et al. (1987) . LTK + cells are LMTK-cells transfected with the expression vector pMl-1 and express HSV-1 thymidine kinase (Blacklaws et al., 1987) . BHK-21 cells were grown in Glasgow modified Eagle's medium (GMEM) with 10% tryptose phosphate broth and 10% calf serum (ETC). Cell lines containing HSV-1 thymidine kinase were grown in ETC supplemented with thymidine, adenosine, guanosine, glycine and methotrexate (Minson et al., 1978) .
Injection of mice.
The various cell lines were harvested by mechanical displacement from growing surfaces with glass beads. The cells were washed three times in phosphate-buffered saline (PBS; 0-15 M-sodium chloride, 0.15 M-sodium phosphate, pH 7,2) and then resuspended to the required concentration in PBS. Mice were injected intraperitoneally with 0.2 ml of cells at 2.5 × 107 cells/ml or with 2-5 x 105 p.f.u./ml CI(101)TLK-.
The immunized mice were challenged with 5 x 104 p.f.u. SC16 injected into the ear pinna (Hill et al., 1975) or by scarifying l07 p.f.u./ml SC16 onto the neck of depilated animals (Simmons & Nash, 1984) .
PAGE of immunoprecipitated antigens.
Radiolabelled infected cell lysates were prepared by infecting confluent BHK-21 monolayers (in 3.5 cm dishes) at an m.o.i, of 10. Starting at 4 h post-infection, infected cells were incubated with methionine-free minimum essential medium supplemented with 1% GMEM containing 50 ~tCi [3sS]methionine (1315 Ci/mmol; Amersham) for 16 h at 37 °C, harvested and then lysed in 1 ml RIPA buffer (50 mM-Tris-HC1 pH 7.2, 150 mM-NaC1, 1% sodium deoxycholate, 0.1% SDS, 1% Triton X-100) plus 2 mMphenylmethylsulphonyl fluoride and 10 units of micrococcal DNase (Sigma) per ml. Lysates were clarified by centrifugation at 100 000 g for 1 h at 4 °C. Immunoprecipitations were performed as described by Richman et al. (1986) on 250 [tl samples of lysate with 10 p.1 immunized mouse serum or 2 pl MAb. MAbs used were HS1 (gift from Dr Y. Kino, The Chemo-Sero-Therapeutic Research Institute, Kumamoto, Japan) specific for gB, and LPI4 (a gift from Dr A. C. Minson, Department of Pathology, Cambridge, U.K.) specific for gD. All samples were boiled for 3 min before use. Samples of 20 ~tl were electrophoresed for 4 h at 35 mA on 10% acrylamideq)-1% N,N'-methylenebisacrylamide resolving gels with 3% acrylamide-0-13% N,N'-methylenebisacrylamide stacking gels using the SDS buffer system of Laemmli (1970) . The gels were then fixed, impregnated with Amplify (Amersham) and dried before exposure to Kodak X-Omat S film at -70 °C.
Determination of antibody titres in serum
Two methods were used to determine antibody titre. (i) Radioimmunoassay. This assay was based on the method reported by Colombatti & Hilgers (1979) . Briefly, antigen plates contained HSV-1 strain SC16-infected or uninfected BHK-2I cells whose non-specific binding sites were blocked with heat-inactivated foetal calf serum (FCS). Serum and 12Si.labelled Protein A (> 30 mCi/mg; Amersham) dilutions were made in PBS plus 10% heat-inactivated FCS. Endpoint titres of antibody were taken as the dilution at which the c.p.m, from infected wells were twice that of uninfected wells.
(ii) Plaque reduction assay. Neutralizing antibody titres were determined by incubating 2 x 102 p.f.u. SC16 with serum overnight at 4 °C and adding rabbit serum as a source of complement for 1 h at 37 °C before titrating the remaining viable virus on BHK-21 cells. Antibody endpoint titres were taken as the dilution that gave 50% reduction in virus titre.
Induction ofcytotoxic T cells. CTLs were prepared as described by Pfizenmaier et al. (1977) with modifications. Briefly, mice were immunized intraperitoneally (i.p.) with 5 x 106 LTKgB cells once, twice (14 days apart) or three times (7 days apart). The spleens of these mice were then removed at various times post-inoculation and made into single cell suspensions as previously described by Nash et al. (l 980) . These cells were cultured for 5 days in RPMI 1640 medium with SCl6-infected, X-irradiated spleen cells (2:1, cells:feeder ratio) and then harvested for use as effectors in a cytotoxicity assay.
CTL assay. Target cells were plated in flat-bottomed 96-well plates in 50 #1 selective medium with 3 lxCi 51chromium per well (sodium chromate in aqueous solution, 250 to 500 ~tCi/mg Cr; Amersham) and incubated overnight at 37 °C with 5 % CO2. Target cells were washed three times, infected for at least 2 h with 50 p.f.u, virus/cell and washed again. The target cells were then incubated with effectors for 6 h at 37°C, 5% CO2 and the percentage specific 51Cr release was determined. All values were obtained from quadruplicate values. Minimum Cr release from targets was always less than 15%.
Titration of virus in mouse tissues. Ear pinnae were removed 5 days post-infection, homogenized in 1 ml ETC and stored at -70 °C before dilution for independent assay of virus on BHK-21 cells (Nash et al., 1980) . To determine latent virus in ganglia, mice received 105 p.f.u. SC16 scarified onto the neck. The mice were sacrificed during the latent phase of infection (i.e. > 30 days post-infection) and the left cervical ganglia (CII, III and IV pooled) were removed. Ganglia were placed into 0-5 ml GMEM with 10% tryptose phosphate broth and cultured for 5 days at 37 °C in 5 % CO:. The ganglia were then homogenized in 1 ml total of ETC and stored at -70 °C before dilution for independent assay on BHK-21 cells. For the purpose of these experiments, any infectious virus recovered from the ganglia was scored as positive for a latent infection.
Results

Antibody response induced by gB and gD
The initial response to be studied over a period of time was the amount of antibody induced by immunization with the cell lines ( Fig. 1 
CI(101)TK-(A)
. Serum was collected at time points shown (the last injection was taken as day 0) and assayed for anti-HSV antibody by radioimmunoassay. Antibody titres were assay endpoints and were expressed as the reciprocal of the highest dilution of antiserum that gave an infected : uninfected BHK binding ratio of 2. Mice immunized with LTK ÷ negative control cells had antiserum titres of < 4 for each time point but these have not been shown. Preimmune sera also had titres of <4 for all groups in (b). radioimmunoassay (data not shown). After one immunization, it could be seen that both cell lines expressing HSV glycoproteins (LTKgB and LTKgD) induced a weak antibody response which was detected initially between day 4 and 7, peaked between day 10 and 20 and declined to undetectable levels (as determined by radioimmunoassay) by day 85 after immunization ( Fig.  l a) . However, very weak antibody levels were still detected on day 200 in sera from mice immunized with LTKgB by immunoprecipitation of radiolabelled HSV-1-infected BHK cell antigen (Fig. 2a) . In contrast a single inoculation with virus produced a longer lasting response (present over the course of the experiment). After two immunizations (40 days apart), higher antibody titres overall were seen (Fig. 1 b) , typical of a secondary response. The antibody level remained elevated for the 200 day time-course. The difference in titres between antiserum from LTKgB-and LTKgD-immunized mice is probably insignificant (being caused by dilution errors and differences in the antigen target in the assay). The antiserum was specific for the immunizing glycoprotein as shown in Fig. 2b) .
Aliquots of immune serum from mice immunized as in Fig. 1 were assayed for neutralizing antibody (in the presence of complement) as described in Methods and the 50% plaque-reducing titres determined are shown in Table 1 . The LTKgB cell line induced very weak neutralizing antibody (titre of 4 after two immunizations). We have previously reported that LTKgB did not induce neutralizing antibody (Blacklaws et al., 1987) but this was using a more stringent plaque reduction assay (5 x 103 p.f.u, used as opposed to 2 x 10 z p.f.u, here). However, LTKgD induced neutralizing antibody titres after one immunization but these had declined to undetectable levels by day 200. After two immunizations neutralizing antibody titres induced by LTKgD were as high as those induced by HSV-1 and these titres persisted over the 200 days of the experiment (Table 1) . These results follow the trend shown by the radioimmunoassay results (Fig. 1) .
Cytotoxic T lymphocyte response induced by gB
Class I-restricted cytotoxic T cells are not induced by gD-1 (Blacklaws et al., 1987; and so the longevity of this type of response cannot be followed with LTKgD. In contrast, a cytotoxic T cell response to LTKgB is induced and was followed after immunization. Animals were injected i.p. with LTKgB cells once, twice or three times and mice sacrificed at various times postinjection. Their spleens were removed and any cytotoxic T cells restimulated with HSV-1 antigen in vitro before use in 51chromium release assays. The results shown (Table 2 ) are the percentage specific 51chromium release from target cells at an effector : target cell ratio of 50 : 1. As can be seen, precursor cytotoxic T lymphocytes specific for gB-1 were present in the spleens from all three groups of mice over 250 days after immunization. The effector cells also recognized three other independently derived L (H-2 k) cell lines expressing gB-1 (data methionine-labelled HSV-l-infected cell lysates and these samples were separated on 10% SDS-polyacrylamide gels. Positive control tracks were infected cell lysates precipitated with the MAbs HS1, specific for gB, and LP14, specific for gD; the precursor'and product forms of both glycoproteins are visible (0). The positions of Mr markers are indicated. Fluorographs of the gels were exposed to film for (a) 19 days and (b) 11 days. These exposures were chosen to show the LTKgB and LTKgD lanes most clearly, but on over-exposure of the gels to film, additional HSV-specific bands became apparent in samples precipitated with anti-HSV serum. not shown). Where there was recognition of HSV-1 (three immunizations, day 254), this was shown to be MHC-restricted (infected 3T3 cells, H-2 d, were not recognized) and HSV-l-specific (HSV-2 strain Bry or vaccinia virus-infected targets were not recognized; data not shown). Lysis was due to cells with a Thyl ÷ L3T4-Lyt2 ÷ (i.e. CD4-CD8 ÷) surface phenotype (data not shown) which is characteristic of MHC class I-restricted T cells.
Protection of mice against viral challenge by immunization with gB or gD
The two cell lines used in this paper have previously been shown to induce a protective response in mice challenged with virulent HSV-1 (Blacklaws et al., 1987) . This is measured in two assays: increased rates of virus clearance from the ear and protection from the establishment of latency.
Firstly, mice were immunized once (Fig. 3) or twice (Fig. 4 ) with cells or virus and then challenged at various times after the last immunization with a standard dose of virus in the ear pinnae. The titres of virus remaining in the pinnae at day 5 post-infection were then determined. The rate of virus clearance at day 6, day 126 and day 187 after one immunization with LTKgB or LTKgD can be seen to decrease with time such that by day 187 no protective response was seen (Fig. 3) . When mice were challenged 7 days after two inoculations with LTKgB there was a 10-to 100-fold reduction in virus titre in the pinnae (compared to the control LTK+-immunized group; Fig. 4 ), but when mice were challenged 161 days after immunization this increased virus clearance had disappeared (Fig. 4) . Similarly, mice immunized twice with LTKgD showed a 104-to 10S-fold reduction in virus titre in the pinnae when challenged on day 7, but again, with a longer interval between immunization and challenge (161 days) this protective response had waned so that there was an insignificant difference between the virus titres in the ear pinnae of LTKgD immunized and control mice (Fig. 4) . This loss of protection with time was also seen in the clearance of virus from the ear pinnae of mice immunized with whole HSV-1 (Fig. 3  and 4) . A second measure of protection is a reduction in the establishment of latent infections in the ganglia of immunized mice upon challenge with a virulent strain of HSV-1. Groups of 10 or more CBA mice were immunized with 5 × 106 LTK ÷, LTKgB or LTKgD cells or 5 x 104 p.f.u. CI(101)TK-i.p. once or twice (14 days apart) and then challenged by scarification of 105 p.f.u. HSV-1 strain SC16 on the left shoulder. Cervical ganglia from these mice were taken 30 days after challenge and explanted into culture to assay for infectious virus. The results have been expressed as the percentage of mice in an immunization group which had a latent infection (Table 3) . As has been previously reported, two immunizations with the cell lines were required before protection from the establishment of a latent infection was seen (Blacklaws et al., 1987) . This did not alter with time after immunization (Table 3) . When mice were immunized twice with LTKgB some protection from latent infection was seen but with time this decreased (40% latent to 73% latent; Table 3 ). However after two immunizations with LTKgD the protection from establishment of latency seen at 15 days after immunization was maintained up to day 186 post-immunization (Table  3 ; 10% and 13 % respectively) as it was by inoculation with HSV-1 (Table 3 ; 11% and 30% respectively). 
Discussion
From the data presented it can be seen that two or more injections with LTKgD were required to induce both a long-lived neutralizing antibody response ( Fig. 1 and Table 1 ) and protection against the establishment of latency (Table 3) . A possible role for neutralizing antibody in HSV infections is inhibition of the transfer of virus from the epithelium to the nervous system (Simmons & Nash, 1985) . The presence of long-lived neutralizing antibody after immunization twice with HSV or LTKgD may be sufficient to protect the mice from latent infections (either by inhibiting spread of virus to the nervous system completely or by lowering the initial threshold of virus to below that required for the establishment of latency). This may also be why there is no protection from latency after one inoculation, when the neutralizing antibody titres induced are much lower (Table 1) . The antibody induced after a primary injection will be of lower affinity than that in a secondary response and this may also be important in determining the contribution of antibody to protection. Immunization with LTKgD did induce increased rates of virus clearance from the periphery if mice were challenged shortly after immunization ( Fig. 3 and 4) but this response did not persist, unlike the antibody response and protection from latency. Therefore there appear to be different immune mechanisms acting to protect mice from latent infections and clearing virus from the periphery. The antibody present in these mice may be involved in protection from the establishment of latency but it is obviously not effective at clearing virus from the periphery (i.e. the ear skin). Rather it seems that once a HSV-1 infection of epidermal cells is established, only T cells may mediate clearance of the virus. This protective lymphocyte population was previously shown to be CD4 ÷ T lymphocytes . We are currently determining the lymphocyte subset involved in protection at the periphery after immunization with LTKgD. It may be the activation state of these cells which is important in determining whether they will be protective in mice and therefore it will be interesting to see whether the activation state declines with time after immunization with cells.
The rate of virus clearance after immunization with LTKgB is never as great as that after inoculation with LTKgD and it was also lost with time after immunization. Again two injections with cells were necessary to give a long-lived antibody response to gB. However, LTKgB was very poor at inducing protection against latent infections. This may be due to the lack of neutralizing antibody induced by LTKgB. There are other reports (Pachl et al., 1987; Marlin et al., 1986; Koga et al., 1986; Spear, 1985) which show the presence of neutralizing epitopes on gB and in our hands a vaccinia virus recombinant expressing gB-1 (HSV-I strain F; Cantin et al., 1987) produces neutralizing antibody titres of 1:64 or more after two inoculations (data not shown) but whether the difference is due to the use of strain KOS gB or the mode of presentation of gB on the cell line is unknown at present.
Recognition of cell lines expressing gB by cytotoxic T lymphocytes induced with the cell line was always better than recognition of HSV-1-infected targets (as previously reported, Blacklaws et al., 1987 and Table 2 ). Glycoprotein B-1 is expressed as a fl), protein (Spear, 1985 ) and so appears late in an HSV-1 infection. It is therefore likely that gB will be competing with other HSV-1 proteins which are expressed earlier in the infection for presentation by the MHC of the host cell (e.g. the immediate early proteins of HSV-1 are also recognized by cytotoxic T cells; Martin et al., 1988; A. A. Nash, unpublished observation) . As gB is constitutively expressed in the cell line it may have a greater chance of being presented to the cytotoxic T cells as is the case with minor histocompatibility antigens. The effect of HSV on cellular degradative pathways is unknown and so the particular epitopes presented on the cell lines compared to infected ceils may also differ.
The presence of precursor cytotoxic T lymphocytes to gB 9 months after immunization shows long-lived cytotoxic T cell memory to this protein. However, this obviously did not aid clearance of virus at the periphery or in protection from the establishment of latent infections. Nevertheless mice immunized once or twice with LTKgB were protected from lethal doses of virus (i.e. 5 x 106 p.f.u.) administered in the ear pinna at day 200 post-immunization (data not shown) showing that some form of immunity is still present in these animals (probably restricting the neural infection which causes death by encephalitis).
In humans infection by HSV is usually by small peripheral doses of virus and so the need to be protected from lethal amounts of virus is not particularly relevant. Rather it is the ability to clear virus quickly from the skin and to stop latent infections occurring which is important. These points were fulfilled here by gD expressed in LTKgD cells, and the protection afforded to the animals was as good as that induced by whole virus (Table 3 and Fig. 3 and 4) . gD has also been shown to induce a protective response in many other different systems, although this response was not always as effective as that produced by HSV. However, it is certainly the most protective HSV protein isolated and tested to date, as shown by using synthetic gD peptides (Eisenberg et al., 1985) , purified gD from mammalian cell lines (Berman et al., 1985; Long et al., 1984; Sanchez-Pescador et al., 1988) , vaccinia virus recombinants expressing gD (Cremer et al., 1985; Paoletti et al., 1984) or baculovirus recombinants expressing gD (Krishna et al., 1989) in both na'~ve mice and guinea-pigs. However, gD alone has not been used as a vaccine in man although it is a constituent of the DNA-free vaccines which are currently on trial (Ashley et al., 1987; Cappel et al., 1982; Mertz et al., 1984) . These mixed protein vaccines will cause seroconversion of seronegatire volunteers but herpes simplex infections may still result with the possibility of ensuing recurrent infections (Ashley et al., 1987) . Our model does not allow us to study recurrence in vivo and little work has been done with vaccination of guinea-pigs which frequently undergo recurrent infections (Scriba, 1977) .
Vaccination of previously non-immune subjects is possible and undoubtedly subunit vaccines against HSV will include glycoproteins D and B. However, from the results presented here, vaccination would need to be repeated at suitable periods of time (e.g. every year) if protection from peripheral infections is to be seen. The data showing protection from latency are most encouraging in that they show that even if the peripheral infection is not decreased (remembering that this is virus replication and not clinical disease such as lesion formation or pain), the number of latently infected carriers of the disease may be reduced and so in time perhaps the prevalence of herpes simplex virus itself.
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